EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM.

Davidson JA, Manghi FP, Yu M, Linetzky B, Landó LF

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists19 Aug 2016Cited by 14 (Europe PMC)

PMID27540883DOI10.4158/ep161337.orPepBankPUB-27540883

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialEfficacy outcome
Hispanic/Latino patients receiving dulaglutide 1.5 mg had a 1.25% HbA1c reduction.
In plain wordsHbA1c fell by 1.25% in Hispanic/Latino patients receiving dulaglutide 1.5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change in Hispanic/Latino patients
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c reduction
1.25%
1.5 mg
HbA1c reduction 95% CI
−1.35 to −1.15%
1.5 mg
Source sentences
Summary
Hispanic/Latino patients receiving dulaglutide 1.5 mg had a reduction in HbA1c of 1.25% (95% confidence interval [CI]: -1.35, -1.15); dulaglutide 0.75 mg had a reduction of 1.07% (95% CI: -1.18, -0.96).
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this post hoc analysis was to assess the efficacy and safety of once-weekly dulaglutide in Hispanic/Latino patients with type 2 diabetes (T2D) in phase 3 AWARD trials 1 to 6.
Summary · context
Hispanic/Latino data at Week 26 were pooled across studies for each dulaglutide dose to analyze the change from baseline in glycosylated hemoglobin (HbA1c), percent to HbA1c goal, and adverse events (AEs).
Summary · context
Change from baseline in HbA1c, change from baseline in weight and hypoglycemia were analyzed by Hispanic/Latino and non-Hispanic/Latino subgroups for each study.
Report a problemFND-2754088301
02HumanRandomized controlled trialEfficacy outcome
Hispanic/Latino patients receiving dulaglutide 0.75 mg had a 1.07% HbA1c reduction.
In plain wordsHbA1c fell by 1.07% in Hispanic/Latino patients receiving dulaglutide 0.75 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change in Hispanic/Latino patients
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c reduction
1.07%
0.75 mg
Source sentences
Summary
Hispanic/Latino patients receiving dulaglutide 1.5 mg had a reduction in HbA1c of 1.25% (95% confidence interval [CI]: -1.35, -1.15); dulaglutide 0.75 mg had a reduction of 1.07% (95% CI: -1.18, -0.96).
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this post hoc analysis was to assess the efficacy and safety of once-weekly dulaglutide in Hispanic/Latino patients with type 2 diabetes (T2D) in phase 3 AWARD trials 1 to 6.
Summary · context
Hispanic/Latino data at Week 26 were pooled across studies for each dulaglutide dose to analyze the change from baseline in glycosylated hemoglobin (HbA1c), percent to HbA1c goal, and adverse events (AEs).
Summary · context
Change from baseline in HbA1c, change from baseline in weight and hypoglycemia were analyzed by Hispanic/Latino and non-Hispanic/Latino subgroups for each study.
Report a problemFND-2754088302

Studies that did not test the peptide alone6

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
HbA1c reductions with dulaglutide were similar in Hispanic/Latino patients and the overall population.
In plain wordsHbA1c reductions with dulaglutide were similar in Hispanic/Latino patients and the overall population.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeHbA1c reduction by ethnicity
Study
n: not reported in source
Comparator
Overall population
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Reductions in HbA1c and percent to goal HbA1c <7% and ≤6.5% were similar between Hispanic/Latino patients and the overall population.
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this post hoc analysis was to assess the efficacy and safety of once-weekly dulaglutide in Hispanic/Latino patients with type 2 diabetes (T2D) in phase 3 AWARD trials 1 to 6.
Summary · context
Hispanic/Latino data at Week 26 were pooled across studies for each dulaglutide dose to analyze the change from baseline in glycosylated hemoglobin (HbA1c), percent to HbA1c goal, and adverse events (AEs).
Summary · context
Change from baseline in HbA1c, change from baseline in weight and hypoglycemia were analyzed by Hispanic/Latino and non-Hispanic/Latino subgroups for each study.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2754088303
04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
Dulaglutide attainment of HbA1c below 7% was similar in Hispanic/Latino patients and the overall population.
In plain wordsThe proportion reaching HbA1c below 7% with dulaglutide was similar in Hispanic/Latino patients and the overall population.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeHbA1c below 7% by ethnicity
Study
n: not reported in source
Comparator
Overall population
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Reductions in HbA1c and percent to goal HbA1c <7% and ≤6.5% were similar between Hispanic/Latino patients and the overall population.
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this post hoc analysis was to assess the efficacy and safety of once-weekly dulaglutide in Hispanic/Latino patients with type 2 diabetes (T2D) in phase 3 AWARD trials 1 to 6.
Summary · context
Hispanic/Latino data at Week 26 were pooled across studies for each dulaglutide dose to analyze the change from baseline in glycosylated hemoglobin (HbA1c), percent to HbA1c goal, and adverse events (AEs).
Summary · context
Change from baseline in HbA1c, change from baseline in weight and hypoglycemia were analyzed by Hispanic/Latino and non-Hispanic/Latino subgroups for each study.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2754088304
05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
Dulaglutide attainment of HbA1c at or below 6.5% was similar in Hispanic/Latino patients and the overall population.
In plain wordsThe proportion reaching HbA1c at or below 6.5% with dulaglutide was similar in Hispanic/Latino patients and the overall population.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeHbA1c at or below 6.5% by ethnicity
Study
n: not reported in source
Comparator
Overall population
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Reductions in HbA1c and percent to goal HbA1c <7% and ≤6.5% were similar between Hispanic/Latino patients and the overall population.
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this post hoc analysis was to assess the efficacy and safety of once-weekly dulaglutide in Hispanic/Latino patients with type 2 diabetes (T2D) in phase 3 AWARD trials 1 to 6.
Summary · context
Hispanic/Latino data at Week 26 were pooled across studies for each dulaglutide dose to analyze the change from baseline in glycosylated hemoglobin (HbA1c), percent to HbA1c goal, and adverse events (AEs).
Summary · context
Change from baseline in HbA1c, change from baseline in weight and hypoglycemia were analyzed by Hispanic/Latino and non-Hispanic/Latino subgroups for each study.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2754088305
06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
Weight change with dulaglutide was similar between Hispanic/Latino and non-Hispanic/Latino subgroups across studies.
In plain wordsWeight changes with dulaglutide were similar in Hispanic/Latino and non-Hispanic/Latino patients.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeWeight change by ethnicity
Study
n: not reported in source
Comparator
Non-Hispanic/Latino patients
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Weight change and hypoglycemia were similar between Hispanic/Latino and non-Hispanic/Latino subgroups for all studies.
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this post hoc analysis was to assess the efficacy and safety of once-weekly dulaglutide in Hispanic/Latino patients with type 2 diabetes (T2D) in phase 3 AWARD trials 1 to 6.
Summary · context
Hispanic/Latino data at Week 26 were pooled across studies for each dulaglutide dose to analyze the change from baseline in glycosylated hemoglobin (HbA1c), percent to HbA1c goal, and adverse events (AEs).
Summary · context
Change from baseline in HbA1c, change from baseline in weight and hypoglycemia were analyzed by Hispanic/Latino and non-Hispanic/Latino subgroups for each study.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2754088306
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
Hypoglycemia with dulaglutide was similar between Hispanic/Latino and non-Hispanic/Latino subgroups across studies.
In plain wordsLow blood sugar with dulaglutide was similar in Hispanic/Latino and non-Hispanic/Latino patients.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeHypoglycemia by ethnicity
Study
n: not reported in source
Comparator
Non-Hispanic/Latino patients
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
Weight change and hypoglycemia were similar between Hispanic/Latino and non-Hispanic/Latino subgroups for all studies.
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this post hoc analysis was to assess the efficacy and safety of once-weekly dulaglutide in Hispanic/Latino patients with type 2 diabetes (T2D) in phase 3 AWARD trials 1 to 6.
Summary · context
Hispanic/Latino data at Week 26 were pooled across studies for each dulaglutide dose to analyze the change from baseline in glycosylated hemoglobin (HbA1c), percent to HbA1c goal, and adverse events (AEs).
Summary · context
Change from baseline in HbA1c, change from baseline in weight and hypoglycemia were analyzed by Hispanic/Latino and non-Hispanic/Latino subgroups for each study.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2754088307
08HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
Treatment-emergent adverse events in Hispanic/Latino dulaglutide patients were consistent with the overall population.
In plain wordsSide effects in Hispanic/Latino dulaglutide patients were consistent with the overall population.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeTreatment-emergent adverse events by ethnicity
Study
n: not reported in source
Comparator
Overall population
Outcome group
Adverse events · Whole body
Source sentences
Summary
Treatment-emergent AEs were consistent with the overall population.
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this post hoc analysis was to assess the efficacy and safety of once-weekly dulaglutide in Hispanic/Latino patients with type 2 diabetes (T2D) in phase 3 AWARD trials 1 to 6.
Summary · context
Hispanic/Latino data at Week 26 were pooled across studies for each dulaglutide dose to analyze the change from baseline in glycosylated hemoglobin (HbA1c), percent to HbA1c goal, and adverse events (AEs).
Summary · context
Change from baseline in HbA1c, change from baseline in weight and hypoglycemia were analyzed by Hispanic/Latino and non-Hispanic/Latino subgroups for each study.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2754088308

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.